Castleman Disease

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

IL6, VEGFA, MLYCD, IL6R, MUC1, SMUG1, TLR4, CXCL13, LRPPRC, ABCG2, MYOM2, HMGA2, AR, ODC1, CD48, JAK1, IL6ST, IL1B, IL1A, HLA-C, FUT4, NM

Drugs

Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, Humanised anti-human Interleukin-6 (IL-6) receptor monoclonal antibody (Genetic Recombination) ( ANTI-HUMAN INTERLEUKIN-6 (IL-6) RECEPTOR MONOCLONAL ANTIBODY (GENETICAL RECOMBINATION) CHUGAI PHARMACEUTICAL CO LTD ), Siltuximab ( SYLVANT ), haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Castleman disease (CD) is a benign lymphoproliferative disorder that may present as a localized or multicentric form (see these terms). The clinical manifestations are heterogeneous, ranging from asymptomatic discrete lymphadenopathy to recurrent episodes of diffuse lymphadenopathy with severe systemic symptoms.